|
US4853332A
(en)
|
1982-10-19 |
1989-08-01 |
Cetus Corporation |
Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of biologically active proteins
|
|
FI82266C
(fi)
|
1982-10-19 |
1991-02-11 |
Cetus Corp |
Foerfarande foer framstaellning av il-2 -mutein.
|
|
US4518584A
(en)
|
1983-04-15 |
1985-05-21 |
Cetus Corporation |
Human recombinant interleukin-2 muteins
|
|
US4530787A
(en)
|
1984-03-28 |
1985-07-23 |
Cetus Corporation |
Controlled oxidation of microbially produced cysteine-containing proteins
|
|
US4572798A
(en)
|
1984-12-06 |
1986-02-25 |
Cetus Corporation |
Method for promoting disulfide bond formation in recombinant proteins
|
|
CA1340265C
(en)
|
1985-01-18 |
1998-12-15 |
Kirston E. Koths |
Oxidation resistant muteins
|
|
US5116943A
(en)
|
1985-01-18 |
1992-05-26 |
Cetus Corporation |
Oxidation-resistant muteins of Il-2 and other protein
|
|
US5206344A
(en)
|
1985-06-26 |
1993-04-27 |
Cetus Oncology Corporation |
Interleukin-2 muteins and polymer conjugation thereof
|
|
US4766106A
(en)
|
1985-06-26 |
1988-08-23 |
Cetus Corporation |
Solubilization of proteins for pharmaceutical compositions using polymer conjugation
|
|
US4816440A
(en)
|
1985-09-26 |
1989-03-28 |
Cetus Corporation |
Stable formulation of biologically active proteins for parenteral injection
|
|
US5425940A
(en)
|
1986-04-09 |
1995-06-20 |
Cetus Oncology Corporation |
Combination therapy using interleukin-2 and tumor necrosis factor
|
|
US4863727A
(en)
|
1986-04-09 |
1989-09-05 |
Cetus Corporation |
Combination therapy using interleukin-2 and tumor necrosis factor
|
|
US5098702A
(en)
|
1986-04-09 |
1992-03-24 |
Cetus Corporation |
Combination therapy using interleukin-2 and tumor necrosis factor
|
|
US4894226A
(en)
|
1986-11-14 |
1990-01-16 |
Cetus Corporation |
Solubilization of proteins for pharmaceutical compositions using polyproline conjugation
|
|
AU3285989A
(en)
|
1987-11-25 |
1989-06-14 |
Cetus Corporation |
Treatment of infections caused by a primary immunodeficiency with interleukin-2
|
|
US5066489A
(en)
|
1988-03-28 |
1991-11-19 |
Cetus Corporation |
Combination therapy of IL-2 and DTIC for the treatment of melanoma
|
|
US4902502A
(en)
|
1989-01-23 |
1990-02-20 |
Cetus Corporation |
Preparation of a polymer/interleukin-2 conjugate
|
|
US5153310A
(en)
|
1989-02-28 |
1992-10-06 |
Du Pont Merck Pharmaceutical Company |
Il-2 analogs containing n-linked glycosylation sites
|
|
NZ234674A
(en)
|
1989-08-02 |
1992-02-25 |
Seragen Inc |
Mutant interleukin-2,dna encoding it, host cells, cytotoxic and toxin-mutant il-2 conjugates
|
|
US5776427A
(en)
|
1992-03-05 |
1998-07-07 |
Board Of Regents, The University Of Texas System |
Methods for targeting the vasculature of solid tumors
|
|
US5229109A
(en)
|
1992-04-14 |
1993-07-20 |
Board Of Regents, The University Of Texas System |
Low toxicity interleukin-2 analogues for use in immunotherapy
|
|
AU6504596A
(en)
|
1995-07-21 |
1997-02-18 |
Rhone-Poulenc Rorer Pharmaceuticals Inc. |
Adeno-associated viral liposomes and their use in transfecting dendritic cells to stimulate specific immunity
|
|
US20040115128A1
(en)
|
1995-09-08 |
2004-06-17 |
Schnitzer Jan E. |
Targeting endothelium for tissue-specific delivery of agents
|
|
EP1442750B1
(en)
|
1997-11-20 |
2012-08-01 |
Vical Incorporated |
Treatment of cancer using cytokine-expressing polynucleotides and compositions therefor
|
|
DE69815707T2
(de)
|
1997-11-20 |
2004-07-01 |
Vical, Inc., San Diego |
Behandlung von krebs durch verwendung von zytokin-exprimierender polynukleotiden und zusammensetzungen dafür
|
|
US6232287B1
(en)
|
1998-03-13 |
2001-05-15 |
The Burnham Institute |
Molecules that home to various selected organs or tissues
|
|
DZ2788A1
(fr)
|
1998-05-15 |
2003-12-01 |
Bayer Ag |
Agonistes et antagonistes selectifs à IL-2.
|
|
US6955807B1
(en)
|
1998-05-15 |
2005-10-18 |
Bayer Pharmaceuticals Corporation |
IL-2 selective agonists and antagonists
|
|
EP1100830B1
(en)
|
1998-07-28 |
2003-10-01 |
Micromet AG |
Heterominibodies
|
|
US6348192B1
(en)
|
1999-05-11 |
2002-02-19 |
Bayer Corporation |
Interleukin-2 mutein expressed from mammalian cells
|
|
DE60031999T2
(de)
|
1999-10-04 |
2007-06-06 |
Novartis Vaccines and Diagnostics, Inc., Emeryville |
Stabilisierte flüssige polypeptid-haltige pharmazeutische zusammensetzungen
|
|
AU2001227966A1
(en)
|
2000-01-20 |
2001-07-31 |
Chiron Corporation |
Methods for treating tumors
|
|
US7306801B2
(en)
|
2000-05-15 |
2007-12-11 |
Health Research, Inc. |
Methods of therapy for cancers characterized by overexpression of the HER2 receptor protein
|
|
US6689353B1
(en)
|
2000-06-28 |
2004-02-10 |
Bayer Pharmaceuticals Corporation |
Stabilized interleukin 2
|
|
US6579521B2
(en)
|
2000-10-20 |
2003-06-17 |
Chiron Corporation |
Methods of therapy for HIV infection
|
|
JP2005501011A
(ja)
|
2001-06-08 |
2005-01-13 |
ユタ ベンチャー ザ セカンド リミテッド パートナーシップ |
組織特異的内皮膜タンパク質
|
|
US7371371B2
(en)
|
2001-08-13 |
2008-05-13 |
University Of Southern California |
Interleukin-2 mutants with reduced toxicity
|
|
US20020187512A1
(en)
|
2001-09-10 |
2002-12-12 |
Nagem Ronaldo Alves Pinto |
Crystal structure of human interleukin-22
|
|
PT1454138E
(pt)
|
2001-12-04 |
2012-03-28 |
Merck Patent Gmbh |
Imunocitoquinas com seletividade modulada
|
|
AU2003280410B8
(en)
|
2002-01-18 |
2009-04-23 |
Zymogenetics, Inc. |
Cytokine receptor zcytor17 multimers
|
|
DE60332358D1
(de)
|
2002-09-09 |
2010-06-10 |
Hanall Pharmaceutical Co Ltd |
Protease-resistente modifizierte interferon alpha polypeptide
|
|
CA2505316C
(en)
|
2002-11-08 |
2014-08-05 |
Ablynx N.V. |
Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
|
|
CN1753912B
(zh)
|
2002-12-23 |
2011-11-02 |
惠氏公司 |
抗pd-1抗体及其用途
|
|
WO2005007121A2
(en)
|
2003-07-18 |
2005-01-27 |
Massachusetts Institute Of Technology |
Mutant interleukin-2(il-2) polypeptides
|
|
DK1648931T3
(da)
|
2003-07-21 |
2011-03-07 |
Transgene Sa |
Multifunktionelle cytokiner
|
|
DE602004031341D1
(de)
|
2003-07-21 |
2011-03-24 |
Transgene Sa |
Multifunktionelle cytokine
|
|
KR100632985B1
(ko)
|
2003-07-26 |
2006-10-11 |
메덱스젠 주식회사 |
생리활성 조절 단백질의 효능 향상 방법 및 그 예시변이체들
|
|
US7132103B2
(en)
|
2003-08-01 |
2006-11-07 |
Enhan Technology Holdings International Co., Ltd. |
Effects of sporoderm-broken germination activated ganoderma spores on treatment of spinal cord injury
|
|
US20050069521A1
(en)
|
2003-08-28 |
2005-03-31 |
Emd Lexigen Research Center Corp. |
Enhancing the circulating half-life of interleukin-2 proteins
|
|
US8454963B2
(en)
|
2003-11-13 |
2013-06-04 |
Musc Foundation For Research Development |
Tissue targeted complement modulators
|
|
MXPA06007236A
(es)
|
2003-12-22 |
2006-08-31 |
Chiron Corp |
Uso de polimorfismos de receptor fc como diagnosticos para estrategias de tratamiento para trastornos de la respuesta inmune.
|
|
MX350383B
(es)
|
2004-01-09 |
2017-09-04 |
Pfizer |
Anticuerpos contra madcam.
|
|
BRPI0508470A
(pt)
|
2004-03-05 |
2007-07-31 |
Chiron Corp |
sistema de teste in vitro para prever toleráncia do paciente aos agentes terapêuticos
|
|
DK1765860T3
(da)
|
2004-05-19 |
2009-03-09 |
Immunocore Ltd |
Ny-ESO-T.cellereceptor med höj affinitet
|
|
US8815235B2
(en)
|
2004-06-02 |
2014-08-26 |
Jan E. Schnitzer |
Tissue-specific imaging and therapeutic agents targeting proteins expressed on lung endothelial cell surface
|
|
AU2006207987B2
(en)
|
2005-01-27 |
2011-09-15 |
Novartis Vaccines And Diagnostics Inc. |
Methods for treating renal cell carcinoma
|
|
JP2008530232A
(ja)
|
2005-02-15 |
2008-08-07 |
ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド |
化学療法剤、ｉｌ−２および場合により抗ｃｄ２０抗体の組み合わせを使用してリンパ腫を処置する方法
|
|
RU2494107C2
(ru)
|
2005-05-09 |
2013-09-27 |
Оно Фармасьютикал Ко., Лтд. |
Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
|
|
EP3263581B2
(en)
|
2005-05-17 |
2025-07-09 |
University of Connecticut |
Compositions and methods for immunomodulation in an organism
|
|
US8008453B2
(en)
*
|
2005-08-12 |
2011-08-30 |
Amgen Inc. |
Modified Fc molecules
|
|
EP1777294A1
(en)
|
2005-10-20 |
2007-04-25 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins
|
|
US8871912B2
(en)
|
2006-03-24 |
2014-10-28 |
Merck Patent Gmbh |
Engineered heterodimeric protein domains
|
|
CA2656700A1
(en)
|
2006-07-06 |
2008-01-10 |
Merck Patent Gesellschaft Mit Beschraenkter Haftung |
Compositions and methods for enhancing the efficacy of il-2 mediated immune responses
|
|
AU2008222678B2
(en)
|
2007-03-07 |
2013-01-17 |
The General Hospital Corporation |
Compositions and methods for the prevention and treatment of autoimmune conditions
|
|
WO2008124858A2
(en)
*
|
2007-04-11 |
2008-10-23 |
F-Star Biotechnologische Forschungs- Und Entwicklungsges. M.B.H. |
Targeted receptor
|
|
US20080260820A1
(en)
|
2007-04-19 |
2008-10-23 |
Gilles Borrelly |
Oral dosage formulations of protease-resistant polypeptides
|
|
WO2009061853A2
(en)
|
2007-11-05 |
2009-05-14 |
Massachusetts Institute Of Technology |
Mutant interleukin-2 (il-2) polypeptides
|
|
CA2742926A1
(en)
|
2007-11-28 |
2009-06-04 |
Universite De Montreal |
Pd-1 modulation and uses thereof
|
|
DE102008023820A1
(de)
|
2008-05-08 |
2009-11-12 |
Aicuris Gmbh & Co. Kg |
Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen
|
|
JP5794917B2
(ja)
|
2008-09-12 |
2015-10-14 |
アイシス・イノベーション・リミテッドＩｓｉｓ Ｉｎｎｏｖａｔｉｏｎｌｉｍｉｔｅｄ |
Ｐｄ−１特異抗体およびその使用
|
|
US8927697B2
(en)
*
|
2008-09-12 |
2015-01-06 |
Isis Innovation Limited |
PD-1 specific antibodies and uses thereof
|
|
NZ592420A
(en)
|
2008-10-02 |
2012-12-21 |
Emergent Product Dev Seattle |
Cd86 antagonist multi-target binding proteins
|
|
US8343497B2
(en)
|
2008-10-12 |
2013-01-01 |
The Brigham And Women's Hospital, Inc. |
Targeting of antigen presenting cells with immunonanotherapeutics
|
|
JP2012506394A
(ja)
|
2008-10-21 |
2012-03-15 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
放射線および免疫サイトカインによる癌治療
|
|
MX2011007647A
(es)
|
2009-01-21 |
2011-09-01 |
Amgen Inc |
Composiciones y metodos para el tratamiento de enfermedades inflamatorias y autoinmunes.
|
|
WO2011020047A1
(en)
|
2009-08-14 |
2011-02-17 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Use of il-15 to increase thymic output and to treat lymphopenia
|
|
CU23734A1
(es)
|
2009-11-27 |
2011-11-15 |
Centro Inmunologia Molecular |
Polipéptidos inmunomoduladores derivados de la il-2 con actividad antagonista de esta citocina útiles en la terapia del cáncer y enfermedades infecciosas crónicas
|
|
TW201134488A
(en)
|
2010-03-11 |
2011-10-16 |
Ucb Pharma Sa |
PD-1 antibodies
|
|
CN102892786B
(zh)
|
2010-03-11 |
2016-03-16 |
Ucb医药有限公司 |
Pd-1抗体
|
|
JP2012053508A
(ja)
*
|
2010-08-31 |
2012-03-15 |
Mitsubishi Heavy Ind Ltd |
数値制御工作機械
|
|
PL2635607T3
(pl)
|
2010-11-05 |
2020-05-18 |
Zymeworks Inc. |
Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC
|
|
CU23923B1
(es)
|
2010-11-12 |
2013-07-31 |
Ct De Inmunología Molecular |
Polipéptidos derivados de la il-2 con actividad agonista
|
|
ES2866674T3
(es)
|
2010-11-12 |
2021-10-19 |
Nektar Therapeutics |
Conjugados de una fracción de IL-2 y un polímero
|
|
US9428567B2
(en)
|
2010-12-22 |
2016-08-30 |
The Board Of Trustees Of The Leland Stanford Junior University |
Antagonists of interleukin-2 receptor
|
|
HUE029139T2
(hu)
|
2011-02-10 |
2017-02-28 |
Roche Glycart Ag |
Mutáns interleukin-2 polipeptidek
|
|
US20120207733A1
(en)
|
2011-02-14 |
2012-08-16 |
Allergan, Inc. |
Treating a Disease of Hyperproliferation Using Retargeted Endopeptidases
|
|
AU2012222833B2
(en)
|
2011-03-03 |
2017-03-16 |
Zymeworks Inc. |
Multivalent heteromultimer scaffold design and constructs
|
|
WO2012119093A1
(en)
|
2011-03-03 |
2012-09-07 |
Board Of Trustees Of The Leland Stanford Junior University |
Superagonists and antagonists of interleukin-2
|
|
KR102220006B1
(ko)
|
2011-03-11 |
2021-02-24 |
아시스땅스 퍼블리끄-오삐또 드 빠리 |
자가면역 - 관련 또는 염증성 장애를 치료하기 위한 저용량 ｉｌ２ 의 용도
|
|
ES2811624T3
(es)
|
2011-03-11 |
2021-03-12 |
Hopitaux Paris Assist Publique |
Régimen de dosificación de IL-2 para tratar lupus eritematoso sistémico
|
|
EA201892619A1
(ru)
|
2011-04-29 |
2019-04-30 |
Роше Гликарт Аг |
Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
|
|
US10081684B2
(en)
|
2011-06-28 |
2018-09-25 |
Whitehead Institute For Biomedical Research |
Using sortases to install click chemistry handles for protein ligation
|
|
EP2742953B1
(en)
|
2011-08-11 |
2021-09-22 |
ONO Pharmaceutical Co., Ltd. |
Therapeutic agent for autoimmune diseases comprising pd-1 agonist
|
|
WO2013043529A1
(en)
|
2011-09-19 |
2013-03-28 |
Emory University |
Bone morphogenetic protein pathway activation, compositions for ossification, and methods related thereto
|
|
CA2854233C
(en)
|
2011-11-04 |
2020-05-12 |
Zymeworks Inc. |
Stable heterodimeric antibody design with mutations in the fc domain
|
|
EP2780364A2
(en)
|
2011-11-18 |
2014-09-24 |
Eleven Biotherapeutics, Inc. |
Proteins with improved half-life and other properties
|
|
CN117264057A
(zh)
|
2012-04-27 |
2023-12-22 |
诺和诺德股份有限公司 |
人cd30配体抗原结合蛋白
|
|
US9844582B2
(en)
|
2012-05-22 |
2017-12-19 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with extended-PK IL-2 and therapeutic agents
|
|
WO2013189516A1
(en)
|
2012-06-18 |
2013-12-27 |
Apeiron Biologics Ag |
Method for treating a gd2 positive cancer
|
|
WO2014004586A1
(en)
|
2012-06-25 |
2014-01-03 |
Zymeworks Inc. |
Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells
|
|
CN104768571B
(zh)
|
2012-07-13 |
2018-11-09 |
酵活有限公司 |
多价异多聚体支架设计和构建体
|
|
CN112587671A
(zh)
|
2012-07-18 |
2021-04-02 |
博笛生物科技有限公司 |
癌症的靶向免疫治疗
|
|
AR092044A1
(es)
|
2012-08-07 |
2015-03-18 |
Roche Glycart Ag |
Inmunoterapia mejorada
|
|
CA2893981C
(en)
|
2012-12-05 |
2021-11-16 |
Shiow-Her Chiou |
Chemokine-cytokine fusion protein and its use
|
|
WO2014100014A1
(en)
|
2012-12-17 |
2014-06-26 |
The Board Of Trustees Of The Leland Stanford Junior University |
Super-2 complexes with antibody to augment il-2 therapy
|
|
EP2950814A4
(en)
*
|
2013-01-31 |
2016-06-08 |
Univ Jefferson |
FUSION PROTEINS BASED ON PD-L1 AND PD-L2 AND USES THEREOF
|
|
US20150259416A1
(en)
|
2014-03-12 |
2015-09-17 |
Biocrine Ab |
Methods for treating and/or limiting development of diabetes
|
|
US9580486B2
(en)
|
2013-03-14 |
2017-02-28 |
Amgen Inc. |
Interleukin-2 muteins for the expansion of T-regulatory cells
|
|
EP2970486B1
(en)
|
2013-03-15 |
2018-05-16 |
Xencor, Inc. |
Modulation of t cells with bispecific antibodies and fc fusions
|
|
EP2968450A4
(en)
|
2013-03-15 |
2016-10-26 |
Angelica Therapeutics Inc |
MODIFIED TOXINS
|
|
BR112015023752B1
(pt)
*
|
2013-03-15 |
2023-11-14 |
Zyngenia, Inc. |
Domínio de reconhecimento modular (mrd), complexo compreendendo mrd e cetuximabe, usos do complexo para inibir a angiogênese e tratar câncer e composição farmacêutica compreendendo o dito complexo
|
|
US10260038B2
(en)
|
2013-05-10 |
2019-04-16 |
Whitehead Institute For Biomedical Research |
Protein modification of living cells using sortase
|
|
US10611830B2
(en)
|
2013-06-06 |
2020-04-07 |
Hefei Lifeon Pharmaceutical Co. Ltd. |
Human antibody against ED-B domain of fibronectin and uses thereof
|
|
WO2015066543A1
(en)
*
|
2013-11-01 |
2015-05-07 |
Board Of Regents, The University Of Texas System |
Targeting her2 and her3 with bispecific antibodies in cancerous cells
|
|
TWI681969B
(zh)
|
2014-01-23 |
2020-01-11 |
美商再生元醫藥公司 |
針對ｐｄ-１的人類抗體
|
|
KR102042246B1
(ko)
|
2014-02-06 |
2019-11-28 |
에프. 호프만-라 로슈 아게 |
인터류킨-2 융합 단백질 및 이의 용도
|
|
ES2792849T3
(es)
|
2014-02-10 |
2020-11-12 |
Univ Emory |
Expresión de polipéptido químico con receptores de linfocitos variables en células inmunes y usos para tratar el cáncer
|
|
ES2723774T3
(es)
|
2014-03-11 |
2019-09-02 |
Molecular Templates Inc |
Proteínas que comprenden regiones de unión, regiones efectoras de la subunidad A de toxina Shiga y motivos señal de localización de retículo endoplasmático carboxi terminal
|
|
EP2918285A1
(en)
|
2014-03-11 |
2015-09-16 |
Université Pierre et Marie Curie (Paris 6) |
Interleukin-2 for treating food allergy
|
|
WO2015164815A1
(en)
|
2014-04-24 |
2015-10-29 |
The Board Of Trustees Of The Leland Stanford Junior University |
Superagonists, partial agonists and antagonists of interleukin-2
|
|
US20170184604A1
(en)
*
|
2014-05-22 |
2017-06-29 |
The General Hospital Corporation |
Dd1alpha receptor and uses thereof in immune disorders
|
|
ES2919749T3
(es)
|
2014-06-11 |
2022-07-28 |
Molecular Templates Inc |
Moléculas dirigidas a células citotóxicas resistentes a la escisión por proteasa
|
|
EP2963057A1
(en)
|
2014-07-02 |
2016-01-06 |
Calypso Biotech SA |
Antibodies to IL-15
|
|
GB2538666A
(en)
|
2014-07-21 |
2016-11-23 |
Delinia Inc |
Molecules that selectively activate regulatory T cells for the treatment of autoimmune diseases
|
|
WO2016020856A2
(en)
|
2014-08-05 |
2016-02-11 |
MabQuest SA |
Immunological reagents
|
|
MA40094B1
(fr)
|
2014-08-06 |
2022-05-31 |
Univ Miami |
Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation
|
|
WO2016025385A1
(en)
|
2014-08-11 |
2016-02-18 |
Delinia, Inc. |
Modified il-2 variants that selectively activate regulatory t cells for the treatment of autoimmune diseases
|
|
JP6800141B2
(ja)
|
2014-08-12 |
2020-12-16 |
マサチューセッツ インスティテュート オブ テクノロジー |
Ｉｌ−２およびインテグリン結合性ｆｃ融合タンパク質による相乗的な腫瘍処置
|
|
MY193723A
(en)
|
2014-08-29 |
2022-10-27 |
Hoffmann La Roche |
Combination therapy of tumor-targeted il-2 variant immunocytokines and antibodies against human pd-l1
|
|
KR102207381B1
(ko)
|
2014-10-23 |
2021-01-27 |
싱 몰레큘러 메디신, 엘엘씨 |
세포내 항원에 대해 지향된 단일 도메인 항체
|
|
EP3875152B1
(en)
|
2014-12-15 |
2024-04-10 |
Washington University |
Compositions and methods for targeted cytokine delivery
|
|
EP3916017A1
(en)
|
2014-12-22 |
2021-12-01 |
PD-1 Acquisition Group, LLC |
Anti-pd-1 antibodies
|
|
US20160206666A1
(en)
|
2014-12-22 |
2016-07-21 |
Synlogic, Inc. |
Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tighten gut mucosal barrier
|
|
WO2016115168A1
(en)
|
2015-01-12 |
2016-07-21 |
Synthorx, Inc. |
Incorporation of unnatural nucleotides and methods thereof
|
|
WO2016141387A1
(en)
|
2015-03-05 |
2016-09-09 |
Xencor, Inc. |
Modulation of t cells with bispecific antibodies and fc fusions
|
|
CN108112254B
(zh)
|
2015-03-13 |
2022-01-28 |
西托姆克斯治疗公司 |
抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法
|
|
RU2749113C2
(ru)
|
2015-04-22 |
2021-06-04 |
Куревак Аг |
Содержащая рнк композиция для лечения опухолевых заболеваний
|
|
EP3292140B1
(en)
|
2015-05-05 |
2022-04-20 |
Rubicon Biotechnology LLC |
Cancer immunotherapeutic
|
|
GB201507908D0
(en)
|
2015-05-08 |
2015-06-24 |
Philogen Spa |
IL2 and TNF immunoconjugates
|
|
CA2994935A1
(en)
|
2015-05-18 |
2016-11-24 |
Ab Initio Biotherapeutics, Inc. |
Sirp polypeptide compositions and methods of use
|
|
EP4424326A3
(en)
|
2015-06-10 |
2024-11-13 |
ImmunityBio, Inc. |
Modified nk-92 cells for treating cancer
|
|
HK1254803A1
(zh)
|
2015-06-23 |
2019-07-26 |
Memorial Sloan Kettering Cancer Center |
新型pd -1的免疫调节剂
|
|
IL256445B2
(en)
|
2015-06-30 |
2023-03-01 |
Nanotics Llc |
Compositions and methods related to absorbent particles
|
|
EA201890391A1
(ru)
|
2015-07-29 |
2018-08-31 |
НАНОТИКС, ЭлЭлСи |
Модульные композиции для утилизации растворимых биомолекул и связанные с этим способы
|
|
TWI603980B
(zh)
*
|
2015-09-01 |
2017-11-01 |
免疫功坊股份有限公司 |
用以治療病理性血栓的聯合接合物構型藥物
|
|
KR102739782B1
(ko)
|
2015-09-11 |
2024-12-09 |
더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 |
생물학적으로 관련된 직교 사이토카인/수용체 쌍
|
|
EA201890790A1
(ru)
|
2015-09-29 |
2018-10-31 |
Селджин Корпорейшн |
Связывающие pd-1 белки и способы их применения
|
|
EP3364944B1
(en)
|
2015-10-22 |
2024-06-12 |
Iltoo Pharma |
Pharmaceutical compositions of il-2
|
|
SG11201803330WA
(en)
|
2015-10-22 |
2018-05-30 |
Juno Therapeutics Gmbh |
Methods for culturing cells and kits and apparatus for same
|
|
KR102876923B1
(ko)
|
2015-10-23 |
2025-10-28 |
화이자 인코포레이티드 |
항-il-2 항체 및 조성물 및 이의 용도
|
|
TW201726149A
(zh)
|
2015-10-23 |
2017-08-01 |
理查 Ｐ 榮漢斯 |
用於免疫療法之組合方法
|
|
US11702477B2
(en)
|
2015-11-06 |
2023-07-18 |
Orionis Biosciences BV |
Bi-functional chimeric proteins and uses thereof
|
|
ES2873846T5
(en)
|
2015-11-19 |
2025-06-23 |
Revitope Ltd |
Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells
|
|
US10597466B2
(en)
|
2015-12-02 |
2020-03-24 |
Fred Hutchinson Cancer Research Center |
Circular tandem repeat proteins
|
|
WO2017096262A1
(en)
|
2015-12-04 |
2017-06-08 |
Jomoco, Corp. |
Compositions and methods to mitigate or prevent an immune response to an immunogenic therapeutic molecule in non-human primates
|
|
EP4026848A1
(en)
|
2015-12-09 |
2022-07-13 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody for reducing the cytokine release syndrome
|
|
WO2017102010A1
(en)
|
2015-12-17 |
2017-06-22 |
Biontech Rna Pharmaceuticals Gmbh |
Novel cytokine fusion proteins
|
|
EP3395366B1
(en)
|
2015-12-21 |
2023-11-22 |
Hefei Lifeon Pharmaceutical Co., Ltd. |
Drug design method, obtained drug and application thereof
|
|
CN116003593A
(zh)
|
2016-01-11 |
2023-04-25 |
苏黎世大学 |
针对人白介素-2的免疫刺激性人源化单克隆抗体及其融合蛋白
|
|
WO2017123675A1
(en)
|
2016-01-11 |
2017-07-20 |
Synlogic, Inc. |
Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells
|
|
WO2017121758A1
(en)
|
2016-01-11 |
2017-07-20 |
Universität Zürich |
Combination therapy comprising a superagonistic antibody against interleukin-2 and a checkpoint blockade agent
|
|
CA3011331C
(en)
|
2016-01-14 |
2025-05-13 |
Intrexon Actobiotics N.V. |
Compositions and methods for the treatment of type 1 diabetes
|
|
US20170204154A1
(en)
|
2016-01-20 |
2017-07-20 |
Delinia, Inc. |
Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
|
|
CA3011374A1
(en)
|
2016-02-05 |
2017-08-10 |
Washington University |
Compositions and methods for targeted cytokine delivery
|
|
US11001631B2
(en)
|
2016-02-05 |
2021-05-11 |
Orionis Biosciences BV |
Clec9A binding agents
|
|
US10888603B2
(en)
|
2016-02-12 |
2021-01-12 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods of treating cancer cells expressing tumor-associated integrins
|
|
EP3211000B1
(en)
|
2016-02-25 |
2019-01-30 |
Provecs Medical GmbH |
Novel immunostimulating vector system
|
|
US11248057B2
(en)
|
2016-03-07 |
2022-02-15 |
Vib Vzw |
CD20 binding single domain antibodies
|
|
JP2019512233A
(ja)
|
2016-03-10 |
2019-05-16 |
ザ・ジョンズ・ホプキンス・ユニバーシティー |
凝集体を含まない単量体のジフテリア毒素融合タンパク質の生成方法及び治療的使用法
|
|
JP6911044B2
(ja)
|
2016-03-16 |
2021-07-28 |
シェ、ヤンホイＸｉｅ Ｙａｎｈｕｉ |
呼吸器系疾患の治療のためのグルココルチコイドとポリエチレングリコール修飾インターロイキン２の組合せ
|
|
CA3017813C
(en)
|
2016-03-17 |
2021-12-07 |
Oslo Universitetssykehus Hf |
Fusion proteins targeting tumour associated macrophages for treating cancer
|
|
CA3044556C
(en)
|
2016-04-12 |
2020-11-17 |
Philogen S.P.A. |
Combination therapy comprising an inflammatory immunocytokine and a chimeric antigen receptor (car)-t cell
|
|
US10906963B2
(en)
|
2016-04-15 |
2021-02-02 |
Philogen S.P.A |
Non-glycosylated anti-tenascin antibody
|
|
EP3448874A4
(en)
|
2016-04-29 |
2020-04-22 |
Voyager Therapeutics, Inc. |
COMPOSITIONS FOR TREATING A DISEASE
|
|
KR102687530B1
(ko)
|
2016-05-04 |
2024-07-25 |
암젠 인크 |
T-조절 세포의 증식을 위한 인터류킨-2 뮤테인
|
|
JP2019518786A
(ja)
|
2016-05-06 |
2019-07-04 |
牧林 王 |
インターロイキンの組み合せ及びその使用
|
|
EP3458485B1
(en)
|
2016-05-19 |
2021-12-29 |
The General Hospital Corporation |
Tethered interleukin-2 to its receptor il-2rbeta, a platform to enhance natural killer and regulatory t cell activity
|
|
KR20190015345A
(ko)
|
2016-05-25 |
2019-02-13 |
에프. 호프만-라 로슈 아게 |
용량 용법 디자인에 관한 재료 및 방법
|
|
CN109890408A
(zh)
|
2016-05-27 |
2019-06-14 |
埃特彼塞斯公司 |
新表位疫苗组合物及其使用方法
|
|
KR20190033483A
(ko)
|
2016-06-03 |
2019-03-29 |
이투빅스 코포레이션 |
인간 파필로마바이러스 (hpv)-연관 질환의 치료를 위한 조성물 및 방법
|
|
CA3026342A1
(en)
|
2016-06-03 |
2017-12-07 |
Etubics Corporation |
Compositions and methods for tumor vaccination using prostate cancer-associated antigens
|
|
JP2019521099A
(ja)
|
2016-06-03 |
2019-07-25 |
エトゥビクス コーポレーション |
Ｈｅｒ２／ｎｅｕを含む、腫瘍ワクチン接種及び免疫療法のための組成物及び方法
|
|
US9567399B1
(en)
|
2016-06-20 |
2017-02-14 |
Kymab Limited |
Antibodies and immunocytokines
|
|
WO2017220704A1
(en)
|
2016-06-22 |
2017-12-28 |
David Klatzmann |
Genetically modified t lymphocytes
|
|
CN109689086A
(zh)
|
2016-07-11 |
2019-04-26 |
国家生物技术研究所公司 |
具有延长的血清半衰期的融合蛋白
|
|
CA3206542A1
(en)
|
2016-07-15 |
2018-01-18 |
Etubics Corporation |
Compositions and methods for alphavirus vaccination
|
|
CA3030447A1
(en)
|
2016-07-15 |
2018-01-18 |
Etubics Corporation |
Compositions and methods for flavivirus vaccination
|
|
GB201614093D0
(en)
|
2016-08-17 |
2016-09-28 |
Autolus Ltd |
Vector
|
|
US10576167B2
(en)
|
2016-08-17 |
2020-03-03 |
Factor Bioscience Inc. |
Nucleic acid products and methods of administration thereof
|
|
WO2018035395A1
(en)
|
2016-08-19 |
2018-02-22 |
Irx Therapeutics, Inc. |
Uses of pd-1/pd-l1 inhibitors and/or ctla-4 inhibitors with a biologic containing multiple cytokine components to treat cancer
|
|
US11453726B2
(en)
|
2016-09-15 |
2022-09-27 |
Quadrucept Bio Limited |
Multimers, tetramers and octamers
|
|
EP3515943A4
(en)
|
2016-09-19 |
2020-05-06 |
Celgene Corporation |
METHODS OF TREATING VITILIGO WITH PD-1 BINDING PROTEINS
|
|
BR112019004733A2
(pt)
|
2016-09-19 |
2019-05-28 |
Celgene Corp |
métodos de tratamento de distúrbios imunes usando proteínas de ligação a pd-1
|
|
CN109906232B
(zh)
|
2016-09-23 |
2023-11-07 |
马伦戈治疗公司 |
包含λ轻链和κ轻链的多特异性抗体分子
|
|
WO2018064594A2
(en)
|
2016-09-29 |
2018-04-05 |
Nantkwest, Inc. |
Hla class i-deficient nk-92 cells with decreased immunogenicity
|
|
US11077172B2
(en)
|
2016-11-08 |
2021-08-03 |
Delinia, Inc. |
IL-2 variants for the treatment of psoriasis
|
|
US20190275133A1
(en)
|
2016-11-10 |
2019-09-12 |
Nektar Therapeutics |
Immunotherapeutic tumor treatment method
|
|
US10011269B2
(en)
|
2016-11-30 |
2018-07-03 |
Ford Global Technologies, Llc |
Identifying in-range fuel pressure sensor error
|
|
BR122020025384B1
(pt)
|
2016-12-13 |
2022-07-12 |
Delinia, Inc |
Proteínas de fusão e dimérica, usos das mesmas e composição farmacêutica
|
|
CN116970059A
(zh)
|
2016-12-22 |
2023-10-31 |
库尔生物制药有限公司 |
T细胞调节性多聚体多肽及其使用方法
|
|
US10232053B2
(en)
|
2016-12-30 |
2019-03-19 |
Trieza Therapeutics, Inc. |
Immunomodulatory oncolytic adenoviral vectors, and methods of production and use thereof for treatment of cancer
|
|
WO2018129188A1
(en)
|
2017-01-04 |
2018-07-12 |
Nanotics, Llc |
Methods for assembling scavenging particles
|
|
US11065345B2
(en)
|
2017-01-04 |
2021-07-20 |
Nanotics, Llc |
Methods for assembling scavenging particles
|
|
BR112019013940A2
(pt)
|
2017-01-06 |
2020-02-11 |
Iovance Biotherapeutics, Inc. |
Método de tratar um câncer com uma população de linfócitos infiltrantes de tumor, processo para preparação de uma população de linfócitos infiltrantes de tumor, população de linfócitos infiltrantes de tumor, e, composição farmacêutica.
|
|
KR102528384B1
(ko)
|
2017-01-06 |
2023-05-02 |
이뮤너티바이오, 인크. |
감소된 cd96/tigit 발현을 갖는 유전자 변형된 nk-92 세포
|
|
WO2018132516A1
(en)
|
2017-01-10 |
2018-07-19 |
Nodus Therapeutics |
Combination tumor treatment with an integrin-binding-fc fusion protein and immune modulator
|
|
US10350266B2
(en)
|
2017-01-10 |
2019-07-16 |
Nodus Therapeutics, Inc. |
Method of treating cancer with a multiple integrin binding Fc fusion protein
|
|
US12350303B2
(en)
|
2017-02-03 |
2025-07-08 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Oncolytic virus therapy
|
|
HRP20250319T1
(hr)
|
2017-02-16 |
2025-05-09 |
Sonnet BioTherapeutics, Inc. |
Fuzijski proteini s domenom za vezanje na albumin
|
|
US11318164B2
(en)
|
2017-03-01 |
2022-05-03 |
Nektar Therapeutics |
Immunotherapeutic treatment method using an interleukin-2 receptor beta-selective agonist in combination with adoptive cell transfer therapy
|
|
IL269000B2
(en)
|
2017-03-15 |
2024-06-01 |
Cue Biopharma Inc |
Methods for modulating an immune response
|
|
BR112019018915A2
(pt)
|
2017-03-15 |
2020-04-14 |
Pandion Therapeutics Inc |
imunotolerância direcionada
|
|
JOP20190224A1
(ar)
|
2017-03-29 |
2019-09-26 |
Iovance Biotherapeutics Inc |
عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي
|
|
RU2761377C2
(ru)
|
2017-04-03 |
2021-12-07 |
Ф. Хоффманн-Ля Рош Аг |
Иммуноконъюгаты антитела к pd-1 с мутантом il-2 или с il-15
|
|
JP7148539B2
(ja)
|
2017-04-03 |
2022-10-05 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
免疫抱合体
|
|
CN108686202A
(zh)
|
2017-04-06 |
2018-10-23 |
张晋宇 |
肿瘤免疫疗法
|
|
TWI788340B
(zh)
|
2017-04-07 |
2023-01-01 |
美商必治妥美雅史谷比公司 |
抗icos促效劑抗體及其用途
|
|
KR20190136076A
(ko)
|
2017-04-13 |
2019-12-09 |
에프. 호프만-라 로슈 아게 |
암 치료 방법에 사용하기 위한 인터루킨-2 면역접합체, cd40 작용제 및 임의적인 pd-1 축 결합 길항제
|
|
US20200224161A1
(en)
|
2017-05-10 |
2020-07-16 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
|
|
CN121343934A
(zh)
|
2017-05-10 |
2026-01-16 |
制药五有限责任公司 |
对补体灭活作用具有抗性的用于治疗癌症的包膜病毒
|
|
WO2018213192A1
(en)
|
2017-05-15 |
2018-11-22 |
University Of Miami |
Materials and methods for subjects at risk for viral reactivation
|
|
JOP20190271A1
(ar)
|
2017-05-24 |
2019-11-21 |
Novartis Ag |
بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة
|
|
JP2020521452A
(ja)
|
2017-05-24 |
2020-07-27 |
パンディオン・セラピューティクス・インコーポレイテッド |
標的化免疫寛容
|
|
EP3630162A1
(en)
|
2017-05-24 |
2020-04-08 |
Novartis AG |
Antibody-cytokine engrafted proteins and methods of use
|
|
WO2019112852A1
(en)
|
2017-12-06 |
2019-06-13 |
Pandion Therapeutics, Inc. |
Targeted immunotolerance
|
|
BR112019024556A2
(pt)
|
2017-05-24 |
2020-06-23 |
Novartis Ag |
Proteínas enxertadas com citocina de anticorpo e métodos para uso no tratamento de câncer
|
|
EP3635097A1
(en)
|
2017-06-05 |
2020-04-15 |
Iovance Biotherapeutics, Inc. |
Methods of using tumor infiltrating lymphocytes in double-refractory melanoma
|
|
SG11201912010XA
(en)
|
2017-06-12 |
2020-01-30 |
Obsidian Therapeutics Inc |
Pde5 compositions and methods for immunotherapy
|
|
EP3638700B8
(en)
|
2017-06-14 |
2024-09-04 |
Shihuida Pharmaceutical Group (Jilin) Co., Ltd., a China corporation |
Proteinaceous heterodimer and use thereof
|
|
AU2018287317B2
(en)
|
2017-06-19 |
2024-06-20 |
Medicenna Therapeutics Inc. |
Uses and methods for IL-2 superagonists, agonists, and fusions thereof
|
|
GB201709808D0
(en)
|
2017-06-20 |
2017-08-02 |
Kymab Ltd |
Antibodies
|
|
US20210017247A1
(en)
|
2017-07-03 |
2021-01-21 |
Torque Therapeutics, Inc. |
Fusion Molecules Targeting Immune Regulatory Cells and Uses Thereof
|
|
CN111246865A
(zh)
|
2017-07-12 |
2020-06-05 |
同生运营公司 |
程序化以在肿瘤细胞中产生免疫调节剂和抗癌治疗剂的微生物
|
|
US20190023760A1
(en)
|
2017-07-24 |
2019-01-24 |
Eth Zurich |
Method for preparing interleukin-2 or interleukin-2 analogues
|
|
WO2019028419A1
(en)
|
2017-08-03 |
2019-02-07 |
Synthorx, Inc. |
CYTOKINE CONJUGATES FOR THE TREATMENT OF PROLIFERATIVE AND INFECTIOUS DISEASES
|
|
SG11202000198QA
(en)
|
2017-08-04 |
2020-02-27 |
Genmab As |
Binding agents binding to pd-l1 and cd137 and use thereof
|
|
US12091463B2
(en)
|
2017-08-09 |
2024-09-17 |
Orionis Biosciences, Inc. |
Clec9A binding agents comprising a recombinant heavy-chain only antibody (VHH)
|
|
EP3665201A4
(en)
|
2017-08-09 |
2021-06-02 |
Orionis Biosciences, Inc. |
CD8 BINDERS
|
|
JP7423511B2
(ja)
|
2017-08-09 |
2024-01-29 |
オリオンズ バイオサイエンス インコーポレイテッド |
Ｐｄ－１およびｐｄ－ｌ１結合物質
|
|
WO2019035938A1
(en)
|
2017-08-16 |
2019-02-21 |
Elstar Therapeutics, Inc. |
MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
|
|
WO2019046815A1
(en)
|
2017-08-31 |
2019-03-07 |
Poseida Therapeutics, Inc. |
TRANSPOSON SYSTEM AND METHODS OF USE
|
|
EP3678691A4
(en)
|
2017-09-07 |
2021-06-09 |
Cue Biopharma, Inc. |
Multimeric t-cell modulatory polypeptides and methods of use thereof
|
|
TW201925235A
(zh)
|
2017-09-07 |
2019-07-01 |
美商信號生物製藥公司 |
具有化學結合位點之抗原呈現多肽及其使用方法
|
|
EP3678677A4
(en)
|
2017-09-07 |
2021-06-16 |
Cue Biopharma, Inc. |
Antigen-presenting polypeptides and methods of use thereof
|
|
TW201920249A
(zh)
|
2017-09-07 |
2019-06-01 |
美商信號生物製藥公司 |
具有結合位點之t細胞調節多聚體多肽及其使用方法
|
|
AU2018329741B2
(en)
|
2017-09-08 |
2025-02-20 |
Poseida Therapeutics, Inc. |
Compositions and methods for chimeric ligand receptor (CLR)-mediated conditional gene expression
|
|
WO2019067766A1
(en)
|
2017-09-27 |
2019-04-04 |
Sigilon Therapeutics, Inc. |
METHODS, COMPOSITIONS AND IMPLANTABLE ELEMENTS COMPRISING ACTIVE CELLS
|
|
US11192943B2
(en)
|
2017-09-30 |
2021-12-07 |
Hefei Lifeon Pharmaceutical Co., Ltd. |
Protein binding to fibronectin B domain
|
|
WO2019084284A1
(en)
|
2017-10-27 |
2019-05-02 |
Coneksis, Inc. |
NK CELLS FOR USE IN THE TREATMENT OF CANCER IN DOGS
|
|
CA3081539A1
(en)
|
2017-11-08 |
2019-05-16 |
Yafei Shanghai Biolog Medicine Science & Technology Co., Ltd. |
Conjugates of biomolecule and use thereof
|
|
CA3082696A1
(en)
|
2017-11-13 |
2019-05-16 |
Extremochem, Lda. |
Neutral glycosylated amides and dianionic glucuronidated acids as stabilizers for biological molecules
|
|
EP4501408A3
(en)
|
2017-11-17 |
2025-04-09 |
Iovance Biotherapeutics, Inc. |
Til expansion from fine needle aspirates and small biopsies
|
|
US20200299349A1
(en)
|
2017-11-21 |
2020-09-24 |
The Board Of Trustees Of The Leland Stanford Junior University |
Partial agonists of interleukin-2
|
|
EP3714041A1
(en)
|
2017-11-22 |
2020-09-30 |
Iovance Biotherapeutics, Inc. |
Expansion of peripheral blood lymphocytes (pbls) from peripheral blood
|
|
CA3084262A1
(en)
|
2017-12-06 |
2019-06-13 |
The Board Of Trustees Of The Leland Stanford Junior University |
Engineered proteins to enhance sensitivity of a cell to il-2
|
|
US10174091B1
(en)
|
2017-12-06 |
2019-01-08 |
Pandion Therapeutics, Inc. |
IL-2 muteins
|
|
EP3720470A4
(en)
|
2017-12-06 |
2021-09-15 |
Pandion Operations, Inc. |
IL-2 MUTEINS AND THEIR USES
|
|
CN111479917A
(zh)
|
2017-12-13 |
2020-07-31 |
詹森生物科技公司 |
经基因修饰以消除T细胞受体和β2-微球蛋白表达的永生化CAR-T细胞
|
|
EP3724885A2
(en)
|
2017-12-15 |
2020-10-21 |
Iovance Biotherapeutics, Inc. |
Systems and methods for determining the beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof and beneficial administration of tumor infiltrating lymphocytes, and methods of use thereof
|
|
EP3728314A1
(en)
|
2017-12-19 |
2020-10-28 |
Kymab Limited |
Bispecific antibody for icos and pd-l1
|
|
US11319355B2
(en)
|
2017-12-19 |
2022-05-03 |
Xencor, Inc. |
Engineered IL-2 Fc fusion proteins
|
|
GB201721338D0
(en)
|
2017-12-19 |
2018-01-31 |
Kymab Ltd |
Anti-icos Antibodies
|
|
EP3502139A1
(en)
|
2017-12-19 |
2019-06-26 |
Philogen S.p.A. |
Antibodies to tumour antigens
|
|
KR102752985B1
(ko)
|
2017-12-20 |
2025-01-10 |
포세이다 테라퓨틱스, 인크. |
Vcar 조성물 및 사용 방법
|
|
CN111527109B
(zh)
|
2017-12-26 |
2024-11-01 |
南京金斯瑞生物科技有限公司 |
以抗体Fc区为骨架的融合蛋白二聚体及其应用
|
|
WO2019131964A1
(ja)
|
2017-12-27 |
2019-07-04 |
協和発酵キリン株式会社 |
Ｉｌ－２改変体
|
|
WO2019129644A1
(en)
|
2017-12-28 |
2019-07-04 |
Julius-Maximilians-Universität Würzburg |
TUMOR NECROSIS FACTOR (TNF) RECEPTOR SUPERFAMILY (TNFRSF) RECEPTOR-ACTIVATING ANTIBODY FUSION PROTEINS WITH FcγR-INDEPENDENT AGONISTIC ACTIVITY (TNFRSF RECEPTOR-ACTIVATING ANTIBODY FUSION PROTEINS WITH FCγR-INDEPENDENT AGONISTIC ACTIVITY; TRAAFFIAA)
|
|
WO2019136459A1
(en)
|
2018-01-08 |
2019-07-11 |
Iovance Biotherapeutics, Inc. |
Processes for generating til products enriched for tumor antigen-specific t-cells
|
|
SG11202006541UA
(en)
|
2018-01-08 |
2020-08-28 |
Iovance Biotherapeutics Inc |
Processes for generating til products enriched for tumor antigen-specific t-cells
|
|
WO2019139896A1
(en)
|
2018-01-09 |
2019-07-18 |
Cue Biopharma, Inc. |
Multimeric t-cell modulatory polypeptides and methods of use thereof
|
|
WO2019144309A1
(en)
|
2018-01-24 |
2019-08-01 |
Beijing Percans Oncology Co. Ltd. |
Cytokine Fusion Proteins
|
|
JP7534215B2
(ja)
|
2018-01-24 |
2024-08-14 |
ベイジン パーカンズ オンコロジー カンパニー リミテッド |
サイトカイン融合タンパク質
|
|
AR114127A1
(es)
|
2018-03-02 |
2020-07-22 |
Lilly Co Eli |
Anticuerpos agonistas contra pd-1 y usos de estos
|
|
KR102849343B1
(ko)
|
2018-03-07 |
2025-08-25 |
포세이다 테라퓨틱스, 인크. |
Cartyrin 조성물 및 사용 방법
|
|
WO2019173832A2
(en)
|
2018-03-09 |
2019-09-12 |
AskGene Pharma, Inc. |
Novel cytokine prodrugs
|
|
MX2021000801A
(es)
|
2018-07-24 |
2021-04-12 |
BioNTech SE |
Agonistas de il2.
|
|
GB2583560A
(en)
|
2018-12-11 |
2020-11-04 |
Admirx Inc |
Fusion protein constructs for complement associated disease
|